The 2016 Centers for Disease Control and Prevention (CDC) Guideline for Prescribing Opioids for Chronic Pain, aggressively promoted by former Health and Human Services (HHS) Secretary Tom Price and CDC Director Tom Frieden, represents one of the most damaging public health missteps in recent U.S. history. Far from curbing the overdose epidemic, CDC guidelines triggered widespread, preventable suffering among legitimate chronic pain patients while leaving illicit fentanyl, the true driver of deaths, largely untouched.
Evidence from the CDC itself, peer-reviewed studies, and real-world data shows three core realities:
- The guidelines were routinely misapplied as rigid mandates, causing serious harm.
- Sharp reductions in legitimate prescribing failed to reduce overdoses and may have driven some patients to deadlier street drugs.
- Forced tapering or abrupt discontinuation dramatically elevated risks of overdose, suicide, untreated pain, and loss of function.
Public officials, including U.S. Senators Bill Cassidy, Mike Crapo, and Ron Wyden, highlighted how the 2016 and 2022 guidelines were often misinterpreted as inflexible rules. These legislators are aware that such errors led to stable patients being forcibly tapered or abandoned, sometimes pushing them toward illegal opioids. They correctly identified contributing factors such as aggressive pharmaceutical marketing, insurance barriers, and limited access to non-opioid care, especially in rural and low-income areas. However, their core premise that physician over-prescribing was the primary driver of the crisis does not withstand scrutiny.
The true drivers of the overdose epidemic
Decades of CDC data, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) clarifications that dependence and tolerance are normal physiological responses rather than addiction, and low rates of treatment-related abuse (one to three per 1,000 clinician-managed patients) confirm that the epidemic was never primarily fueled by legitimate prescriptions. Mental health history is far more predictive of overdose or suicide risk than opioid analgesic prescription itself. Even Morphine Milligram Equivalent (MME) thresholds lack robust scientific grounding for individual patient care.
The CDC’s own 2022 Clinical Practice Guideline explicitly acknowledged some of these failures, admitting that policies derived from the 2016 version were misapplied far beyond its intent through rigid dosage caps, rapid tapers without patient input, patient dismissal, and inappropriate application to cancer or palliative care populations. These actions caused untreated pain, severe withdrawal, psychological distress, illicit drug substitution, overdose, and suicide. The 2022 CDC update stressed that recommendations were meant to be flexible, voluntary, and individualized, not inflexible standards imposed by insurers, pharmacies, or regulators.
Both guidelines were treated as hard rules that encouraged forced or abrupt tapering, underweighting chronic pain patients’ needs while overemphasizing misuse reduction. The 2022 revision, while an improvement, retained narrative language and MME concepts that continued to invite misuse. Public agencies, insurers, and state policies turned clinical guidance into blunt instruments, producing undertreatment of pain and structural bias against appropriate opioid therapy, even as overdoses shifted overwhelmingly to illicit synthetics.
The numbers are conclusive. Opioid prescriptions plummeted more than 52 percent since 2012 (from 260.5 million to 125.7 million in 2024, with total MME dosage down 65 percent). Yet, overdose deaths have surged for years, driven almost entirely by illicit fentanyl. Only about 1.3 percent of recent overdose victims had an active legitimate opioid prescription. Recent provisional data show a nearly 25 percent drop in overdoses in the 12 months ending March 2025. This drop is attributable to harm reduction, naloxone access, treatment expansion, and shifts in the illicit supply, not further prescription cuts. A 2025 Lancet analysis confirms that the crisis is multifactorial, with deaths heavily driven by illicit fentanyl saturation in the drug supply. Modeling shows that aggressive prescription reductions can produce short-term spikes in heroin and fentanyl deaths as patients substitute to deadlier alternatives.
The human toll of forced tapering
The human toll is well-documented. A 2023 UC Davis study of over 110,000 stable long-term opioid patients linked tapering to more emergency department visits, hospitalizations, reduced primary care engagement, and poorer adherence to medications for co-occurring conditions. Studies and reports from Human Rights Watch, pain medicine societies, the American Medical Association (AMA), and patient advocates describe a “silent public health crisis of untreated chronic pain,” with rapid tapers tied to tripled overdose risk, increased suicides, mental health crises, worsened function, and eroded trust in health care. The AMA’s 2025 report reinforces that individualized, patient-centered care, not arbitrary restrictions, must guide treatment decisions.
As a 2024 STAT analysis noted, blaming clinicians for overprescribing never solved the epidemic. The crisis has multiple roots, including social and economic conditions, limited addiction treatment capacity, and illicit synthetics. It is not a simple story of “too many prescriptions.” Reducing or forcibly tapering prescribed opioids in isolation is ineffective and can actively harm patients.
The AMA, American Academy of Pain Medicine, U.S. Pain Foundation, and Harvard Medical School experts have echoed these concerns, noting that massive prescribing reductions and expanded monitoring programs failed to curb overdoses because of illicit fentanyl, methamphetamine, and cocaine. Forced tapers contributed to illicit drug substitution and higher national overdose rates. At SYNC-2026, the nation’s largest harm reduction conference in March 2026, experts reinforced that the 2016 guidelines were shaped more by political agendas than rigorous science, with many known methodological errors.
A call for evidence-based pain care
Patients have suffered enough. Policymakers, regulators, insurers, and legislators must act decisively. It is time to prioritize individualized, evidence-based care, protect stable patients from forced tapers, reject MME mythology, expand access to non-opioid therapies without barriers, and redirect resources toward the illicit drug supply, harm reduction, and genuine addiction treatment.
The evidence from the CDC’s own admissions, peer-reviewed research, and the lived reality of millions is clear. The time for half-measures is over.
Kayvan Haddadan is a physiatrist and pain management physician, and president and medical director of Advanced Pain Diagnostic & Solutions, a multidisciplinary pain management practice in California that he founded in 2012. A physician and surgeon licensed by the Medical Board of California, he is double board-certified in pain medicine and physical medicine and rehabilitation. He is also certified in controlled substance registration through the DEA and serves as a qualified medical examiner through California’s Department of Industrial Relations Division of Workers’ Compensation.
Dr. Haddadan earned his Bachelor of Science degree from the College of Alborz in Tehran, Iran, and his medical degree from Shahid Beheshti University of Medical Sciences. He later received his Educational Commission for Foreign Medical Graduates certification in Philadelphia, completed an internship in medical surgery at Loyola University Medical Center’s Stritch School of Medicine in Illinois, and finished his residency in physical medicine and rehabilitation at the same institution. He completed his fellowship in pain medicine at California Pacific Medical Center’s Pacific Pain Treatment Center and also trained in medical acupuncture for physicians at the University of California, Los Angeles David Geffen School of Medicine.
Dr. Haddadan has contributed to 29 research publications across multiple specialties, including pain management, cardiology, pulmonology, endocrinology, gastroenterology, and infectious disease. His work has examined topics such as hyperlipidemia in high cardiovascular risk patients, hyperuricemia and gout management, type 2 diabetes and hypertension, chronic obstructive pulmonary disease and asthma therapies, influenza treatment, irritable bowel syndrome, and opioid related complications in chronic pain care. His research has also included clinical outcome studies in spinal cord stimulation and award-winning presentations on neuropathic pain management and neuromuscular disorders.
